Candidiasis - Pipeline Review, H1 2019 - ResearchAndMarkets.com
The "Candidiasis - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
The "Candidiasis
- Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's
offering.
Candidiasis - Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Candidiasis (Infectious Disease), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases. The Candidiasis (Infectious Disease) pipeline
guide also reviews of key players involved in therapeutic development
for Candidiasis and features dormant and discontinued projects.
The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown
stages are 4, 5, 2, 26, 7 and 1 respectively. Similarly, the
Universities portfolio in Preclinical and Discovery stages comprises 11
and 10 molecules, respectively.
Candidiasis (Infectious Disease) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Candidiasis (Infectious Disease). -
The pipeline guide reviews pipeline therapeutics for Candidiasis
(Infectious Disease) by companies and universities/research institutes
based on information derived from company and industry-specific
sources. -
The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and
undisclosed stages. -
The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing
and collaboration details, R&D brief, MoA & other developmental
activities. -
The pipeline guide reviews key companies involved in Candidiasis
(Infectious Disease) therapeutics and enlists all their major and
minor projects. -
The pipeline guide evaluates Candidiasis (Infectious Disease)
therapeutics based on mechanism of action (MoA), drug target, route of
administration (RoA) and molecule type. -
The pipeline guide encapsulates all the dormant and discontinued
pipeline projects. -
The pipeline guide reviews latest news related to pipeline
therapeutics for Candidiasis (Infectious Disease)
Reasons to buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies. -
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage. -
Find and recognize significant and varied types of therapeutics under
development for Candidiasis (Infectious Disease). - Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies. -
Plan mergers and acquisitions meritoriously by identifying key players
and it's most promising pipeline therapeutics. -
Formulate corrective measures for pipeline projects by understanding
Candidiasis (Infectious Disease) pipeline depth and focus of
Indication therapeutics. -
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope. -
Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
Key Topics Covered
- Introduction
- Candidiasis - Overview
- Candidiasis - Therapeutics Development
- Candidiasis - Therapeutics Assessment
- Candidiasis - Companies Involved in Therapeutics Development
- Candidiasis - Drug Profiles
- Candidiasis - Dormant Projects
- Candidiasis - Discontinued Products
- Candidiasis - Product Development Milestones
- Appendix
Companies Mentioned
- Amplyx Pharmaceuticals Inc.
- APEIRON Biologics AG
- Bakker Medical S.r.l.
- Beta Pharma Inc.
- Biosergen AS
- Cellix Bio Pvt. Ltd.
- Cidara Therapeutics Inc.
- Fox Chase Chemical Diversity Center Inc.
- General Biologicals Corp.
- Grupo Ferrer Internacional S.A.
- Helix BioMedix Inc.
- iCo Therapeutics Inc.
- LipoSeuticals Inc.
- Matinas BioPharma Holdings Inc.
- Nanomerics Ltd.
- Nosopharm S.A.S.
- Novabiotics Ltd.
- NovaDigm Therapeutics Inc.
- Novartis AG
- Pulmocide Ltd.
- Scynexis Inc.
- Sealife Pharma GmbH
- Viamet Pharmaceuticals Inc.
- Visterra Inc.
- Wellstat Vaccines LLC
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ilwxem
View source version on businesswire.com: https://www.businesswire.com/news/home/20190416005550/en/